1
|
Zhang H, Li C, Li J, Hou S, Chen D, Yan H, Chen S, Liu S, Yin Z, Yang X, Tan J, Huang X, Zhang L, Fang J, Zhang C, Li W, Guo J, Lei D. Next-generation sequencing improves molecular epidemiological characterization of thalassemia in Chenzhou Region, P.R. China. J Clin Lab Anal 2019; 33:e22845. [PMID: 30809867 PMCID: PMC6528559 DOI: 10.1002/jcla.22845] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Revised: 12/19/2018] [Accepted: 01/03/2019] [Indexed: 12/23/2022] Open
Abstract
Objectives Thalassemia is a highly prevalent monogenic inherited disease in southern China. It is important to collect epidemiological data comprehensively for proper prevention and treatment. Methods In this study, blood samples collected from 15 807 residents of Chenzhou were primarily screened by hematological tests. A total of 3973 samples of suspected thalassemia carriers were further characterized by combined next‐generation sequencing (NGS) and Gap‐PCR. Results In total, 1704 subjects were diagnosed as thalassemia carriers with a total prevalence rate of 10.78%, including 943 α‐thalassemia carriers, 708 β‐thalassemia carriers, and 53 composite α and β‐thalassemia carriers. The prevalence rates of α‐thalassemia, β‐thalassemia, and composite α and β‐thalassemia were 5.97%, 4.48%, and 0.34%, respectively. Meanwhile, we characterized 19 α‐thalassemia variations and 21 β‐thalassemia variations in thalassemia carriers. Approximately 2.88% of thalassemia carriers would be missed by traditional genetic analysis. In addition, four novel thalassemia mutations and one novel abnormal hemoglobin mutation were identified. Conclusions Our data suggest a high prevalence of thalassemia and a diverse spectrum of thalassemia‐associated variations in Chenzhou. Also, combined NGS and Gap‐PCR is an effective thalassemia screening method. Our findings might be helpful for prevention and treatment of thalassemia in this region.
Collapse
Affiliation(s)
- Haoqing Zhang
- Center of Prenatal Diagnosis, Chenzhou No. 1 People's Hospital, Chenzhou, China
| | - Caiyun Li
- Center of Prenatal Diagnosis, Chenzhou No. 1 People's Hospital, Chenzhou, China
| | - Jianbiao Li
- BGI-Shenzhen, Shenzhen, China.,China National GeneBank, BGI-Shenzhen, Shenzhen, China
| | - Shuai Hou
- Center of Prenatal Diagnosis, Chenzhou No. 1 People's Hospital, Chenzhou, China
| | - Danjing Chen
- Center of Prenatal Diagnosis, Chenzhou No. 1 People's Hospital, Chenzhou, China
| | - Haiying Yan
- Center of Prenatal Diagnosis, Chenzhou No. 1 People's Hospital, Chenzhou, China
| | - Shiping Chen
- BGI Genomics, BGI-Shenzhen, Shenzhen, China.,Clinical Laboratory of BGI Health, BGI-Shenzhen, Shenzhen, China
| | - Saijun Liu
- BGI Genomics, BGI-Shenzhen, Shenzhen, China
| | - Zhenzhen Yin
- BGI-Shenzhen, Shenzhen, China.,China National GeneBank, BGI-Shenzhen, Shenzhen, China
| | - Xiaoqin Yang
- BGI Genomics, BGI-Shenzhen, Shenzhen, China.,Clinical Laboratory of BGI Health, BGI-Shenzhen, Shenzhen, China
| | - Jufang Tan
- Center of Prenatal Diagnosis, Chenzhou No. 1 People's Hospital, Chenzhou, China
| | - Xiaoyan Huang
- BGI Genomics, BGI-Shenzhen, Shenzhen, China.,Clinical Laboratory of BGI Health, BGI-Shenzhen, Shenzhen, China
| | - Liming Zhang
- BGI Genomics, BGI-Shenzhen, Shenzhen, China.,Clinical Laboratory of BGI Health, BGI-Shenzhen, Shenzhen, China
| | - Junbin Fang
- BGI Genomics, BGI-Shenzhen, Shenzhen, China.,Clinical Laboratory of BGI Health, BGI-Shenzhen, Shenzhen, China
| | - Caifen Zhang
- BGI Genomics, BGI-Shenzhen, Shenzhen, China.,Clinical Laboratory of BGI Health, BGI-Shenzhen, Shenzhen, China
| | - Wei Li
- BGI Genomics, BGI-Shenzhen, Shenzhen, China
| | - Jian Guo
- BGI-Shenzhen, Shenzhen, China.,China National GeneBank, BGI-Shenzhen, Shenzhen, China
| | - Dongzhu Lei
- Center of Prenatal Diagnosis, Chenzhou No. 1 People's Hospital, Chenzhou, China
| |
Collapse
|
2
|
Tran Houangkeo THY, Bodereau V, Riou J, Pissard S. Hb Savaria [α49(CE7)Ser→Arg; HBA2: c.150C > A]: A New Case and Complete Description. Hemoglobin 2016; 40:267-9. [PMID: 27221333 DOI: 10.1080/03630269.2016.1177539] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Hb Savaria [α49(CE7)Ser→Arg; HBA2: c.150C > A] is a rare hemoglobin (Hb) variant, initially described in Eastern Europe but present worldwide. It belongs to that class of variants which can be confused with Hb S [β6(A3)Glu→Val; HBB: c.20A > T] by automated protein analysis and thus needs special tests for proper identification. Because it could arise from different nucleotide substitutions and according to the rules of the Human Genome Variation Society (HGVS) nomenclature, three 'Hb Savaria' variants are possible. In the case reported here it resulted from the HBA2: c.148A > C change.
Collapse
Affiliation(s)
- Thi Hai Yen Tran Houangkeo
- a Laboratoty of Metabolic Biochemistry , Assistance Publique-Hôpitaux De Paris (APHP), Centre Hospitalier Universitaire (CHU) Pitié Salpétrière , Paris , France
| | - Virginie Bodereau
- b Laboratory of Genetics , Assistance Publique-Hôpitaux De Paris (APHP), Groupe Hospitalier Universitaire (GHU) Henri Mondor , Créteil , France
| | - Jean Riou
- b Laboratory of Genetics , Assistance Publique-Hôpitaux De Paris (APHP), Groupe Hospitalier Universitaire (GHU) Henri Mondor , Créteil , France
| | - Serge Pissard
- b Laboratory of Genetics , Assistance Publique-Hôpitaux De Paris (APHP), Groupe Hospitalier Universitaire (GHU) Henri Mondor , Créteil , France .,c Inserm Institut Mondor De Recherche Biologique (IMRB) U955 Eq 2, Universite Paris Est Crèteil (UPEC) , Créteil , France
| |
Collapse
|